Pharmacokinetics, Safety, and Tolerability of Imipenem / Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial [PDF]
Imipenem/cilastatin/relebactam is approved for the treatment of serious gram-negative bacterial infections in adults. This study assessed the pharmacokinetics (PK), safety, and tolerability of a single dose of imipenem/cilastatin/relebactam (with a fixed
Tøndel, Camilla +9 more
core +2 more sources
Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020 [PDF]
Objectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (
Alicia Hernández-Cabezas +70 more
core +3 more sources
Imipenem and relebactam pharmacokinetics in peritoneal fluid: microdialysis reveals infection-independent penetration. [PDF]
Imipenem/relebactam is a promising therapy for complicated intra-abdominal infections caused by carbapenem-resistant Enterobacterales species. However, data on tissue-site pharmacokinetics are limited.
Tong H +7 more
europepmc +2 more sources
Purpose: Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases.
Delgado Valverde, María Mercedes +6 more
core +1 more source
The inoculum effect (IE) is a well-known phenomenon with beta-lactams. At the same time, the IE has not been extensively studied with carbapenem/carbapenemase inhibitor combinations.
Kamilla N. Alieva +15 more
core +1 more source
Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies) [PDF]
Imipenem-relebactam is a novel β-lactam-β-lactamase inhibitor combination. We evaluated the in vitro activity of imipenem-relebactam and comparators against Enterobacterales clinical isolates recovered in 8 Spanish and 11 Portuguese intensive care units (
Pássaro, Leonor +50 more
core +2 more sources
Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus [PDF]
Infections caused by Mycobacterium abscessus are increasing in prevalence in cystic fibrosis patients. This opportunistic pathogen′s intrinsic resistance to most antibiotics has perpetuated an urgent demand for new, more effective therapeutic ...
Rathbone, Dan +11 more
core +1 more source
Molecular Basis of Class A β-lactamase Inhibition by Relebactam [PDF]
β-Lactamase production is the major β-lactam resistance mechanism in Gram-negative bacteria. β-Lactamase inhibitors (BLIs) efficacious against serine β-lactamase (SBL) producers, especially strains carrying the widely disseminated class A enzymes, are ...
Mulholland, Adrian +19 more
core +1 more source
Background: Despite the availability of new options (ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam and cefiderocol), it is still very difficult to treat infections caused by metallo-β-lactamase (MBLs)-producers resistant to ...
Cécile Emeraud +2 more
core +1 more source
Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains [PDF]
Relebactam is an important beta-lactamase inhibitor for certain aerobic organisms, but alone it has no antianaerobic activity, with most anaerobes having MICs of ≥32 μg/ml with the exception of a very few strains.
Ellie J. C. Goldstein +9 more
core +1 more source

